News By Tag
News By Location
Pharmacogenomics Startup GENETWORx Launches New Website
GENETWORx has launched a new website to highlight their drug-response DNA testing that helps patients, healthcare professionals and plan sponsors determine the right dose, of the right medication, for the best patient outcome.
Scott Blevins, a pharmacist with a strong business background, including an MBA from the Robins School of Business at the University of Richmond, is the founder of GENETWORx. "My experience in the technology side of healthcare, combined with my clinical knowledge, tells me that pharmacogenomics is the future of pharmacology,"
Blevins continued, "offering patients, doctors, pharmacists and health plan sponsors an easy, cost-effective way to determine the optimum dosage for each patient, for a large percentage of commonly-prescribed medications, will reduce over- and under-dosing. Which will in turn reduce medical costs. Everybody wins."
The enzymes tested by GENETWORx - CYP450 enzymes 2C19, 2C9 and 2D6 - show response to a number of anticoagulants, anti-convulsants, antihistamines, anti-fungals, narcotics, and other drugs. The full GENETWORx test menu is linked here (http://www.genetworx.com/
Our mission is to deliver meaningful Personalized Medicine results to patients, providing health care professionals the necessary tools to leverage their knowledge and truly individualize treatment plans based on a patient’s DNA – Utilizing the latest technology in DNA sequencing to help provide the right medications, at the right dose, and effectively lower overall healthcare expenditures while delivering the best health outcome for the patient.
# # #
WellCentrix is helping healthcare communicate with its customers: patients, peers, plan sponsors, technology partners.